The MMRF was honored for the 15th year for outstanding stewardship of donors’ funds.
The Multiple Myeloma Research Foundation (MMRF) received a 4-star rating from Charity Navigator, America’s largest independent evaluator of charitable donations, for demonstrating strong financial health and commitment to accountability and transparency.
This is the 15th time the MMRF has earned this coveted recognition.
The coveted 4-star rating, the highest honor Charity Navigator bestows, indicates that “The Multiple Myeloma Research Foundation exceeds industry standards and outperforms most charities.” According to Charity Navigator, “this sets the MMRF apart from its peers and demonstrates to the public its trustworthiness.”
“Charity Navigator’s 4-star rating underscores our tireless commitment to accountability, efficiency and measurable results” said Paul Giusti, CEO of the MMRF. “Our commitment to our patients and donors remains focused on maximizing every dollar we invest.”
About the Multiple Myeloma Research Foundation (MMRF)
The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $400 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.
Pembrolizumab Plus Chemo Improves Overall Survival in Resectable Gastric Cancer
Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL
Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL
Durvalumab Plus Chemo Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer
2 Commerce Drive
Cranbury, NJ 08512